Twist Bioscience (NASDAQ:TWST) Upgraded by ValuEngine to Hold

Twist Bioscience (NASDAQ:TWST) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday, ValuEngine reports.

Separately, Zacks Investment Research downgraded shares of Twist Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, October 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $26.55.

Shares of NASDAQ TWST traded up $0.85 during mid-day trading on Friday, hitting $22.36. The stock had a trading volume of 206,800 shares, compared to its average volume of 221,702. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.96 and a current ratio of 7.18. Twist Bioscience has a 1 year low of $13.99 and a 1 year high of $35.95. The business has a 50 day moving average price of $23.93 and a two-hundred day moving average price of $26.98. The firm has a market cap of $748.20 million and a P/E ratio of -0.88.

In related news, CFO James M. Thorburn sold 10,000 shares of Twist Bioscience stock in a transaction on Monday, August 19th. The shares were sold at an average price of $29.81, for a total value of $298,100.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Patrick Weiss sold 14,729 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $22.86, for a total transaction of $336,704.94. Over the last ninety days, insiders sold 281,143 shares of company stock worth $7,532,938. 29.40% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of Twist Bioscience by 90.2% in the second quarter. JPMorgan Chase & Co. now owns 1,997,857 shares of the company’s stock worth $56,220,000 after buying an additional 947,399 shares during the period. BlackRock Inc. increased its position in Twist Bioscience by 320.7% during the 2nd quarter. BlackRock Inc. now owns 1,532,141 shares of the company’s stock valued at $44,447,000 after purchasing an additional 1,167,949 shares during the period. Vanguard Group Inc. increased its position in Twist Bioscience by 321.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,055,474 shares of the company’s stock valued at $30,619,000 after purchasing an additional 805,251 shares during the period. Emerald Advisers LLC increased its position in Twist Bioscience by 146.5% during the 2nd quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock valued at $16,814,000 after purchasing an additional 344,463 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its position in Twist Bioscience by 156.0% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock valued at $15,204,000 after purchasing an additional 319,373 shares during the period. 42.64% of the stock is currently owned by institutional investors.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Read More: What is a back-end load?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.